Shares of the insulin pump maker continued their powerful performance last month.
News & Analysis: Tandem Diabetes Care
New software technology will make its insulin pumps even more effective.
Investors counting on the company's dominance of the closed-loop artificial pancreas market might want to temper their expectations.
If you want to see your investment in the biotech market grow two-fold, these are the top stocks to buy.
Is the optimism surrounding this insulin pump maker justified?
Including one or more of these three top medical-device companies in your portfolio now could be savvy.
There are some highly promising diabetes treatments entering the market that investors should know about.
The insulin pump maker once again delivered stellar quarterly results.
TNDM earnings call for the period ending September 30, 2019.
The growth stock cooled off a bit last month but has still managed to scorch the market with a 51% year-to-date gain.